2025 Q4 -tulosraportti
Vain PDF
22 päivää sitten
Tarjoustasot
First North Denmark
Määrä
Osto
4 115
Myynti
Määrä
222
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 425 | - | - | ||
| 86 | - | - | ||
| 468 | - | - |
Ylin
2,84VWAP
Alin
2,835VaihtoMäärä
0 979
VWAP
Ylin
2,84Alin
2,835VaihtoMäärä
0 979
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 201 | 1 201 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 201 | 1 201 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 9.10.2025 | ||
2025 H1 -tulosraportti 27.8.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sitten · MuokattuIt is not sustainable for the case that there should be such long intervals between orders for a growth company with BQ’s visions. Difficult to see the light at the end of the tunnel despite the new Pharma director and the capital he brought into the company. I know history says it can be difficult to sell into new companies without a longer test phase, but with more than 2 months since the last order news, it honestly makes me more uncertain about the future. One can hope they have things in the pipeline that haven't been announced, but right now it's just the hope I'm holding onto 😅 Anyone more optimistic?
·12.2.I have seen somewhat mixed opinions on the equipment the times I have encountered it in work contexts. I'm just not sure I fully understand the investment case. Isn't it "just" a total bacterial count based on an enzymatic assay? I understand there are some advantages compared to an ATP test, but it's probably still almost only relevant in contexts where total count makes sense. Unlike the food sector where there are tons of bacteria, and those you want to avoid are dangerous even in very small quantities.
·18.2.For example, for Legionella, there is synergy between the total amount of biofilm and the risk of Legionella growth. So in many cases, the total amount will be perfectly OK. It therefore provides a good starting point for taking precautions.·18.2.That's right, but legionella specifically is one of those I've encountered who have sold a system. The complication arises when the customer then has to figure out the relationship between general bacterial load and legionella, and probably also between harmless legionella and dangerous legionella. That's not to say it can't easily be a great idea and that it can be done well. But market penetration will probably then depend on how quickly one can prove all the individual use cases, and whether one can get (or have oneself) an environment of implementation/applications experts. Again, not necessarily anything against the company's solution, I was just surprised that it is publicly listed, where patience is a bit lower.
·11.2.Trading statement Q4: ups and downs. Deducting the previous quarters, the revenue was: Hardware 336t Recurring 1.978t Other 504t Hardware is again very disappointing, and this is what represents the new business. Recurring performed surprisingly well. Strange that it fluctuates so much from quarter to quarter - have they perhaps put it on offer to maximize revenue before New Year? Overall an okay quarter, which however does not specifically point towards a brighter future. And their guidance for 2026 is not impressive either. A somewhat increasing revenue, but still large deficits.
·9.2.We are soon reaching 2 months where there hasn't been an order. Do you ever think it will get into gear and generate 30-50 million annually?
·4.2.The financial report will probably come after market close again. The numbers will not be anything to cheer about. I am more excited about the guidance for this year and more long-term, as well as if they have anything new to announce regarding strategy. Perhaps the new strategic advisor (Steen Søndergaard, former CEO for ChemoMetec) has provided some input.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
22 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sitten · MuokattuIt is not sustainable for the case that there should be such long intervals between orders for a growth company with BQ’s visions. Difficult to see the light at the end of the tunnel despite the new Pharma director and the capital he brought into the company. I know history says it can be difficult to sell into new companies without a longer test phase, but with more than 2 months since the last order news, it honestly makes me more uncertain about the future. One can hope they have things in the pipeline that haven't been announced, but right now it's just the hope I'm holding onto 😅 Anyone more optimistic?
- ·12.2.I have seen somewhat mixed opinions on the equipment the times I have encountered it in work contexts. I'm just not sure I fully understand the investment case. Isn't it "just" a total bacterial count based on an enzymatic assay? I understand there are some advantages compared to an ATP test, but it's probably still almost only relevant in contexts where total count makes sense. Unlike the food sector where there are tons of bacteria, and those you want to avoid are dangerous even in very small quantities.·18.2.For example, for Legionella, there is synergy between the total amount of biofilm and the risk of Legionella growth. So in many cases, the total amount will be perfectly OK. It therefore provides a good starting point for taking precautions.·18.2.That's right, but legionella specifically is one of those I've encountered who have sold a system. The complication arises when the customer then has to figure out the relationship between general bacterial load and legionella, and probably also between harmless legionella and dangerous legionella. That's not to say it can't easily be a great idea and that it can be done well. But market penetration will probably then depend on how quickly one can prove all the individual use cases, and whether one can get (or have oneself) an environment of implementation/applications experts. Again, not necessarily anything against the company's solution, I was just surprised that it is publicly listed, where patience is a bit lower.
- ·11.2.Trading statement Q4: ups and downs. Deducting the previous quarters, the revenue was: Hardware 336t Recurring 1.978t Other 504t Hardware is again very disappointing, and this is what represents the new business. Recurring performed surprisingly well. Strange that it fluctuates so much from quarter to quarter - have they perhaps put it on offer to maximize revenue before New Year? Overall an okay quarter, which however does not specifically point towards a brighter future. And their guidance for 2026 is not impressive either. A somewhat increasing revenue, but still large deficits.
- ·9.2.We are soon reaching 2 months where there hasn't been an order. Do you ever think it will get into gear and generate 30-50 million annually?
- ·4.2.The financial report will probably come after market close again. The numbers will not be anything to cheer about. I am more excited about the guidance for this year and more long-term, as well as if they have anything new to announce regarding strategy. Perhaps the new strategic advisor (Steen Søndergaard, former CEO for ChemoMetec) has provided some input.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
4 115
Myynti
Määrä
222
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 425 | - | - | ||
| 86 | - | - | ||
| 468 | - | - |
Ylin
2,84VWAP
Alin
2,835VaihtoMäärä
0 979
VWAP
Ylin
2,84Alin
2,835VaihtoMäärä
0 979
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 201 | 1 201 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 201 | 1 201 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 9.10.2025 | ||
2025 H1 -tulosraportti 27.8.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
2025 Q4 -tulosraportti
Vain PDF
22 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 9.10.2025 | ||
2025 H1 -tulosraportti 27.8.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sitten · MuokattuIt is not sustainable for the case that there should be such long intervals between orders for a growth company with BQ’s visions. Difficult to see the light at the end of the tunnel despite the new Pharma director and the capital he brought into the company. I know history says it can be difficult to sell into new companies without a longer test phase, but with more than 2 months since the last order news, it honestly makes me more uncertain about the future. One can hope they have things in the pipeline that haven't been announced, but right now it's just the hope I'm holding onto 😅 Anyone more optimistic?
- ·12.2.I have seen somewhat mixed opinions on the equipment the times I have encountered it in work contexts. I'm just not sure I fully understand the investment case. Isn't it "just" a total bacterial count based on an enzymatic assay? I understand there are some advantages compared to an ATP test, but it's probably still almost only relevant in contexts where total count makes sense. Unlike the food sector where there are tons of bacteria, and those you want to avoid are dangerous even in very small quantities.·18.2.For example, for Legionella, there is synergy between the total amount of biofilm and the risk of Legionella growth. So in many cases, the total amount will be perfectly OK. It therefore provides a good starting point for taking precautions.·18.2.That's right, but legionella specifically is one of those I've encountered who have sold a system. The complication arises when the customer then has to figure out the relationship between general bacterial load and legionella, and probably also between harmless legionella and dangerous legionella. That's not to say it can't easily be a great idea and that it can be done well. But market penetration will probably then depend on how quickly one can prove all the individual use cases, and whether one can get (or have oneself) an environment of implementation/applications experts. Again, not necessarily anything against the company's solution, I was just surprised that it is publicly listed, where patience is a bit lower.
- ·11.2.Trading statement Q4: ups and downs. Deducting the previous quarters, the revenue was: Hardware 336t Recurring 1.978t Other 504t Hardware is again very disappointing, and this is what represents the new business. Recurring performed surprisingly well. Strange that it fluctuates so much from quarter to quarter - have they perhaps put it on offer to maximize revenue before New Year? Overall an okay quarter, which however does not specifically point towards a brighter future. And their guidance for 2026 is not impressive either. A somewhat increasing revenue, but still large deficits.
- ·9.2.We are soon reaching 2 months where there hasn't been an order. Do you ever think it will get into gear and generate 30-50 million annually?
- ·4.2.The financial report will probably come after market close again. The numbers will not be anything to cheer about. I am more excited about the guidance for this year and more long-term, as well as if they have anything new to announce regarding strategy. Perhaps the new strategic advisor (Steen Søndergaard, former CEO for ChemoMetec) has provided some input.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
4 115
Myynti
Määrä
222
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 425 | - | - | ||
| 86 | - | - | ||
| 468 | - | - |
Ylin
2,84VWAP
Alin
2,835VaihtoMäärä
0 979
VWAP
Ylin
2,84Alin
2,835VaihtoMäärä
0 979
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 201 | 1 201 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 201 | 1 201 | 0 | 0 |